SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Launched by MASSIVE BIO, INC. · Feb 24, 2018

Keywords

ClinConnect Summary

The SYNERGY-AI trial is exploring how artificial intelligence (AI) can help match cancer patients with the most suitable clinical trials. This study focuses on patients with various types of advanced cancer, including those with solid tumors and blood cancers. By using a special program that analyzes genetic information and other tumor characteristics, the trial aims to improve how patients are connected to research studies that may offer new treatment options.

To participate, individuals must have specific cancer-related biomarkers that can be identified through tests done by their healthcare provider. Eligible participants can expect to be part of a process that helps them explore potential clinical trials tailored to their unique cancer profile. This trial is currently recruiting patients of all ages and genders, and it's important to note that some individuals may not qualify if they have serious health issues or are receiving hospice care. Through this study, researchers hope to enhance the understanding of how AI can support cancer treatment and improve outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pts with solid and hematological malignancies;
• • Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
• • These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
• • Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
• Exclusion Criteria:
• • ECOG PS \> 2;
• • Abnormal organ function;
• • Hospice enrollment